Eli Lilly is progressing its experimental obesity and type 2 diabetes drug retatrutide into Phase 3 trials, following late-stage data showing significant weight loss and metabolic improvements.

Retatrutide belongs to a new class of drugs known as triple agonists, targeting three key metabolic pathways simultaneously. In earlier trials, the drug demonstrated weight loss outcomes exceeding those typically seen with current GLP-1-based therapies, alongside improvements in blood glucose control.

The move into Phase 3 is a critical milestone. It signals that multi-hormone therapies are transitioning from experimental approaches to potential mainstream treatments.

“The most important thing is that what this isn’t is just another stronger GLP-1,” says metabolic health specialist and founder of Go Metabolic, Dr Dan Reardon. “In the phase 3 trial which they have published, it does only relate to people with type 2 diabetes. It definitely shows very significant reductions in HbA1c [a long-term blood sugar marker that shows your average blood glucose levels over the past 2–3 months] and also body weight over quite a short period of time. So that’s compared to if it had just been managed with diet and exercise alone. I think that’s really promising.

“And I think certainly from the perspective of the broader market, it would suggest that it’s showing that the combination, or rather triple agonists, or the combination of the three pieces of the Retatrutide peptide, makes a lot of sense in terms of reducing adiposity, improving blood sugar regulation, and obviously any sort of potential dangerous fat accumulation. So it’s very interesting. The one important thing is that we don’t know what it’s like compared to the other GLP-1s that are currently on the market.”

Triple agonist mechanism in obesity drugs

Retatrutide works by activating three hormone receptors: GLP-1, GIP and glucagon.

These hormones regulate appetite, insulin secretion, energy expenditure and glucose metabolism. By targeting all three, the drug aims to deliver a broader metabolic effect than single- or dual-agonist therapies.

Triple agonist obesity drugs are therapies that simultaneously activate multiple metabolic hormone receptors to influence appetite, glucose regulation and energy balance in a coordinated way.

This multi-pathway approach reflects a shift in how obesity is being treated. Rather than focusing on appetite suppression alone, these drugs aim to reprogram metabolic systems more comprehensively.

What is retatrutide and how does it work?

Retatrutide is an investigational triple agonist drug that targets GLP-1, GIP and glucagon receptors to regulate appetite, insulin response and energy expenditure, leading to significant weight loss and improved metabolic health outcomes in clinical trials.

Why multi-hormone therapies are gaining momentum

The success of GLP-1 drugs such as semaglutide and tirzepatide has reshaped the obesity treatment market. However, they primarily act through appetite suppression and insulin modulation.

Retatrutide extends this model by incorporating glucagon receptor activation, which can increase energy expenditure and fat metabolism.

This matters because obesity is not a single-pathway condition. It involves complex interactions between hormones, behaviour and energy balance. Multi-hormone therapies are designed to address that complexity more directly.

The clinical data suggests this approach may produce greater weight loss and potentially more durable metabolic changes.

Metabolic engineering as a new therapeutic model

The emergence of triple agonists signals a broader shift toward what could be described as metabolic engineering.

Instead of treating symptoms or isolated pathways, pharmaceutical companies are designing drugs that reshape the body’s regulatory systems.

This aligns with a wider trend across health technology and longevity: moving from reactive treatment to proactive optimisation of biological systems.

In this context, obesity drugs are becoming platforms for broader metabolic control, with potential applications beyond weight loss, including cardiovascular health and long-term disease risk reduction.

“The biggest unanswered question from the trial is how does it compare head-to-head with other GLP-1s or with GLP-1 combinations, so semaglutide and teszepatide,” says Reardon, who also works as an A&E doctor in the NHS..

“The other thing is how is it going to stack up with regards to side effects? So I think my gut feeling is that the gastrointestinal side effects of Retatrutide in the dose escalation are probably worse than the GLP-1. So obviously, we’d need to see how that stacks up in a direct comparison.

“We also have no actual idea what happens when you come off the Retatrutides. So there’s certainly increasing numbers of trials now that show the drastic return of body weight and return to baseline cardiometabolic risk with the GLP-1s. So it’s going to be really interesting to see what happens with Retatrutide with regards to that.”

Competitive landscape in next-generation obesity drugs

Eli Lilly is currently leading in the development of multi-hormone therapies, building on the success of its dual agonist tirzepatide.

Other pharmaceutical companies are also exploring combinations of GLP-1 with additional pathways, but triple agonists represent one of the most advanced and differentiated approaches in development.

The commercial stakes are significant. The global obesity drug market is projected to reach tens of billions of dollars annually, driven by rising prevalence of obesity and increasing acceptance of pharmacological treatment.

“In terms of where does Retatrutide sit in the drug option landscape, well, of course, it’s not available at the moment, so the only way that it can be viewed is perhaps more so as a strategy,” says Reardon.

“We’ve obviously seen very, very good results with Semaglutide and Tirzepatide in terms of when people have taken the medications. I have very clear ideas and thoughts about what happens after you stop taking them, the writing’s on the wall for that, but if we just come at the perspective of comparing drug to drug to drug, there’s no comparison yet between retatrutide and, for example, Semaglutide. So that’s obviously going to be very interesting to see when that does happen.

“The only thing that you can say at the moment is that it’s more of a strategy as opposed to where it will actually sit in the landscape. My gut feeling is that it will sit at the top because of the other effects as a result of the glucagon agonists, but that’s just my thinking at this particular point in time.”

Future implications for obesity and metabolic health treatment

Over the next five to ten years, multi-hormone therapies are likely to redefine the standard of care for obesity and related metabolic conditions.

First, treatment efficacy is expected to increase, with greater average weight loss and improved metabolic markers.

Second, these drugs may expand into preventative use cases, targeting individuals earlier in the metabolic disease pathway.

Third, they could integrate with digital health platforms, combining pharmacology with behavioural interventions and data-driven monitoring.

Retatrutide’s progression into Phase 3 therefore represents more than a single drug milestone. It signals the maturation of a new therapeutic paradigm: one where metabolic systems are targeted in a coordinated, multi-layered way to deliver measurable health outcomes at scale.

“One of the things I’m perhaps more interested in with Retatrutide is actually what happens with regards to fitness levels,” says Reardon. “Because one of the benefits of the glucagon agonist, well, there’s two things really. One is increased energy expenditure. So what will be the effect, or what effect might that have on people’s adherence to exercise and potential benefits from exercise?

Another thing is to do with liver health, because one of the things with the glucagon agonists is that we see an increase in the amount of liver fat that gets broken down. So are we going to see drastic improvements in fatty liver and overall liver health, which would obviously be a very good thing?

And if we see improvements in fatty acid oxidation and therefore improved metabolic flexibility, then I think that’s going to be something really interesting.

Reardon also hopes that drugs like Retatrutide could be influential in altering patients’ experience of improving their health. “The thing that I’m most interested in with regards to Retatrutide is what benefits will we see from the effects of the GLP1 agonist. I think that’s the really exciting thing.

“There are so many dieting companies where we have seen they’ve been able to get people’s weight down and reduce calories. So I understand that the GLP1 and the GLP make it easier. But the thing that the fitness and weight loss world has never been successful at really is getting people to feel the benefits of exercise, because that’s what keeps us exercising, the fact that we feel the benefits, we feel good.

“I just wonder whether the GLP-1 agonist part is something that actually might start to help people feel good as a result of exercise because of the improvements in energy performance, increasing the energy expenditure, improving metabolic flexibility.”

What to watch next

The next phase of data will determine whether Retatrutide is simply more effective, or fundamentally different. Three things matter:

• Head-to-head trials against semaglutide and tirzepatide to establish relative efficacy and tolerability.
• Post-treatment outcomes, particularly whether weight regain and cardiometabolic risk return at the same rate seen with current GLP-1 therapies.
• Functional benefits, including effects on energy expenditure, exercise adherence and liver health.

If Retatrutide can demonstrate meaningful advantages across these areas, it won’t just extend the current model of obesity treatment, it will reset expectations of what pharmacological metabolic control can achieve.